Events And

NASH-TAG Conference

Jan 07, 2023 at 12:30 PM EST

Oral Presentation: Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Non-invasive Markers of Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: Results of a Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Presenter: Stephen Harrison, M.D., Chairman and Co-Founder of Pinnacle Clinical Research and Summit Clinical Research in San Antonio, TX

Supporting Materials


Investor Contact

Richard Eisenstadt
Chief Financial Officer



Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail